12th European Congress Perspectives in Lung Cancer
Lingotto Conference and Exhibition Centre
Via Nizza 280 10126 Torino
Torino, Italy
It is our pleasure to invite you to the 12th European Congress: Perspectives in Lung Cancer, 11-12 March 2011, in Torino, Italy. Focusing on state-of-the art information on treatment and diagnosis, this Congress will provide attendees with valuable data for the management of patients with lung cancer.

Guided by an interactive format, Perspectives in Lung Cancer will not only provide a comprehensive overview of the most significant advances in lung cancer treatment, but will also leave attendees with valuable take home information. Lectures, meet-the-expert sessions, and panel discussions, will aid attendees in confirming their current practices, increase their knowledge of lung cancer and optimize their patient care.

Nearly 1,000 physicians, nurses, and other healthcare professionals attend Perspectives in Lung Cancer annually, making it one of THE must-attend lung cancer conferences. Past participants value the scope and depth of the information on disease biology, management, and research presented, and many return each year for the newest updates. As lung cancer research and treatment are ever-evolving, this comprehensive focus on the multimodal management of lung cancer in Europe is sure to be a rewarding educational experience for attendees to share.

We hope you will be able to join us for this valuable, educational two day meeting. Set against the backdrop of Torino, a flourishing, industrious and cosmopolitan European city, which enjoys state-of-theart technology and architectural developments, this Congress is not to be missed! 


Schedule of Presentations:

Friday, March 11, 2011
08:15:00 Welcome and introduction Giorgio Vittorio Scagliotti
08:25:00 Session I | Epidemiology of lung cancer
08:30:00 Molecular epidemiology of lung cancer
08:50:00 Epigenetic changes in lung cancer
09:10:00 Lung cancer in never smokers | A new molecular and clinical entity Lucini Crino
09:30:00 Clinical case on new staging system for lung cancer
09:45:00 Keynote lecture
09:50:00 The c-met oncogene in human cancer
10:20:00 Coffee break
10:35:00 Session II | Endoscopy, imaging and pathology in lung cancer
10:40:00 The spectrum of optics in the management of lung cancer Thomas G. Sutedja
11:20:00 Minimally invasive surgical techniques for the diagnosis and treatment of lung cancer
11:40:00 PET in lung cancer
12:00:00 Hot topics in diagnostic pathology
12:20:00 Lunch break
14:15:00 Session III | Thoracic radiation therapy and lung cancer
14:20:00 Physical and biological basis of modern radiotherapy
14:40:00 Combining chemotherapy and radiotherapy in stage III NSCLC Ramaswamy Govindan
15:00:00 Targeted therapies and thoracic radiation therapy Umberto Ricardi
15:20:00 Management of acute and chronic side effects of thoracic radiation therapy Cécile Le Pechoux
15:40:00 Clinical case of combined modality therapy
16:00:00 Coffee break
16:25:00 Session IV | Targeted therapies in lung cancer | What we have learned?
16:30:00 Insulin-like growth factor receptor (IGF-R1) inhibitors Luis Paz Ares
16:50:00 VEGF- Multiple TKIs Martin Reck
17:10:00 c-MET and ALK inhibitors Ramaswamy Govindan
17:30:00 HDAC and PARP inhibitors
17:50:00 Targeting cancer stem cells
18:00:00 Wrap up of day one
18:15:00 Adjourn
Saturday, March 12, 2011
08:00:00 Welcome and introduction Pieter E. Postmus
08:05:00 Session V | Supportive care in lung cancer
08:10:00 Role of bisphosphonates in lung cancer
08:30:00 Role of ESA in lung cancer | Therapeutic guidelines and clinical practice
08:50:00 Role of G-CSF in lung cancer | Therapeutic guidelines and clinical practice
09:10:00 The optimal management of lung cancer related symptoms Kristiaan Nackaerts
09:30:00 Clinical case on TNM staging Pieter E. Postmus
09:50:00 Coffee break
10:15:00 Session VI | Changing the treatment paradigms in lung cancer
10:20:00 Treatment choices in front line management of NSCLC
10:40:00 Maintenance strategies in NSCLC Silvia Novello
11:00:00 Systemic treatment for recurrent or refractory NSCLC Christian Manegold
11:40:00 Lights and shadows in the systemic treatment of SCLC
12:00:00 Lunch break
13:25:00 Session VII | Elderly and PS2 patients
13:30:00 Any limit to surgery for patients over 75 years old?
13:50:00 The best choice for systemic treatment in the elderly
14:10:00 Is a pharmacogenomic approach a doable strategy in the elderly? GEORGE SIMON
14:30:00 PS2 patients | Treat or not treat? Rogerio Lilenbaum
14:50:00 Clinical case
15:05:00 Session VIII | Rare thoracic tumors
15:10:00 Malignant thymoma
15:30:00 Neuroendocrine tumors other than SCLC
15:50:00 Clinical Case on TNM staging of carcinoid Pieter E Postmus
16:00:00 Adjourn
3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.